Company intelligence / Profile preview
Nurix Therapeutics
San Francisco, California, United Statesnurixtx.com ↗
- Ownership
- Public · NRIX
- Development stage
- Phase 1
01
Overview
Nurix has reported positive clinical data for its BTK degrader NX‑5948 in relapsed/refractory CLL/SLL patients, including those with poor prognostic features. NX‑2127 also shows promise as a bifunctional degrader of BTK and cereblon neosubstrates. The company’s pipeline includes wholly owned and partnered assets targeting cancer and autoimmune indications, with several candidates progressing through early clinical or preclinical development.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small moleculesTargeted protein degradersDegrader-Antibody Conjugates (DACs)
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
Request access →03
Partnerships
Gilead Sciences – collaboration on multiple targets including GS–6791/IRAK4 programSanofi – partnership on STAT6 program with up to $465M in milestones & royaltiesPfizer (via Seagen acquisition) – partnership for Degrader-Antibody Conjugate technology/DACs
04
Financials
- Market cap
- $2.7B
- Total revenue
- $9M
- Enterprise value
- $2.3B
Beyond the preview
Go deeper on Nurix Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nurix Therapeutics.